Дроспиренон – гестаген ХХI века с антиминералокортикоидной активностью
- Авторы: Пасман НМ1
-
Учреждения:
- Новосибирский государственный университет
- Выпуск: Том 6, № 2 (2004)
- Страницы: 92-96
- Раздел: Статьи
- URL: https://ogarev-online.ru/2079-5831/article/view/27577
- ID: 27577
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаСписок литературы
- Sitruk-Ware R.The pharmacological profile of different progestins: the special case of Drospirenone. Drospirenon more than a progestogen. 11Th World Congress of Gynecological Endocrinology. Florence, Italy, February 26: р. 4–5.
- Rosenberg M.G, Waugh. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gyn 1998; 179: 577–82.
- Сметник В.П., Тумилович Л.Г. Неоперативная гинекология: Руководство для врачей.-3-е изд., М.: Медицинское информационное агентство, 2002.
- Тихомиров А.Л., Лубнин Д.М. Основы репродуктивной гинекологии. М.:Медпрактика. М., 2003.
- Foidart J.M. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care 2000; 5: 25–33.
- Foidart J.M, Wuttke W, Bouw G.M.F. Comparative investigation of a contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5: 124–34.
- Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of unique progestogen. Contraception 2000; 41: 875–86.
- Mansour D. Yasmin – a new oral contraceptive, a new progestogen: the reasons why. Eur J Contracept Reprod Health Care 2000; 5: 9–16.
- Futtman U, Krattenmacher R, Slater E.P et al. The novel progestine drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenics potencial. Contraception 1996; 54: 243–51.
- Muhn P, Fuchmann U, Fritzemeier K. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 199; 761: 311–35.
- Oelkers W, Berger V, Bolik A et al. Dyhydrodrospirenone, a new progestogen with antimineralocorticoid activity: effect on ovulation, electrolyte excretion and the rennin - angiotensin – aldosterone system in normal women. J Clin Endocrinol Metab 1991; 73: 837–42.
- Foidart J.M. Added benefits of drospirenone for compliance. In.: Drospirenon more than a progestogen. 11Th World Congress of Gynecological Endocrinology. Florence, Italy, February 26: р. 10–11
- Huber J, Foidart J.M, Wuttke W. Efficacy and tolerability monophasic oral contraceptives containing ethinilestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5: 25–34.
- Rosenbaum P, Shimidt W, Helmerhorst F.M. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinilestradiol. Eur J Contracept Reprod Health Care 2000; 5: 16–24.
- Ludicke F, Johannisson E, Helmerhorst P et al. Effect of combinated oral contraceptive containing 3 mg of drospirenone and 30 µg ethinilestradiol on the human endometrium. Fertil Steril 2001; 76: 102–7.
- Boschitsch E, Skarabis H, Wuttke W. et al. the acceptability of novel oral contraceptive containing drospirenone and its effect on welll - being. Eur J Contracept Reprod Health Care 2000; 5: 3–40.
- Brown C, Ling F, Wan J. A new monophasic contraceptive containing drospirenone: effect of perimenstrual symptoms. J Reprod Med 2002; 47: 14–22.
- Freeman E.W, Kroll R, Rapkin A et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Women’s Health Gend Vased Med 2001; 10: 561–9.
- Sillem M, Shcneidereit R et al. Anwendung des drospirenone - haltigenoralen Kontrazeptivumsin Langzyklus. Frauenarzt. 2003; 44: 876–81.
- Oelkers W, Foidart J.M, Dombrovicz N. Effect of a new oral contraceptive containing antimineralocorticoid progestogen drospirenone on the rennin - angiotensin – aldosterone system, body weigth, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–21.
- Oelkers W, Helmerhorst F.M, Wuttke W. Effect of an oral contraceptives containing drospirenone on the rennin - angiotensin - aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 204–13.
- Gaspard U, Scheen A, Endicard J et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinilestradiol combinated with drospirenone or desogestrel on carbohydrate metabolism. Contraception 2003; 67: 423–9.
Дополнительные файлы
